Common use of Presentation of products Clause in Contracts

Presentation of products. The contractor will produce a written manuscript in MS Word for the draft and final review. The final style and format of the products will be agreed by NICE Team and the PDG. The production will be undertaken according to the methodology set out in the Methods for development of NICE public health guidance 2012 and as summarised below. Example manuscripts will be provided by NICE Team. The draft and final reviews will address the research questions, the populations groups, areas and outcomes identified in the final Scope (sections 4.1, 4.2, 4.4 and 4.5) and used in the original evidence reviews. The detailed parameters, style and format of the draft and final reports are to be agreed with the NICE Team before writing commences. A stand-alone executive summary is to be included in the draft and final reviews. The executive summary will include all of the evidence statements (see Chapter 5 and 6 of the Methods for development of NICE public health guidance 2012) and the linked references. At least one draft manuscript is to be submitted first, this is commented on by the NICE Team and then the final draft manuscript is prepared in line with comments received and re-submitted to NICE team in readiness for mailing to the PHAC. The NICE team will ensure that the finalised draft will then be forwarded to the PHAC. See Annex 2 for the required timetable for the production of the draft and final reviews. The reviews will remain strictly confidential until the guidance consultation phase. Draft and final reviews will include the following areas (further details are provided in Appendix L of the methods manual): Executive summary Introduction Context in which the review is set Aims and objectives of the review Research questions Operational definitions Identification of possible equality and equity issues Review team Methodology Literature search and abstract appraisal Retrieval of data and full paper appraisal (including inclusion/exclusion criteria) Selection of studies for inclusion (including flow diagram which is to be adapted from NICE template) Quality assessment and applicability appraising Methods of data extraction, synthesis and presentation (including formulation of evidence statements) Findings Overview of studies for each research question Narrative summary of the evidence for each selected theme Evidence statements for each selected theme Applicability of the evidence to the UK populations in the scope Meta-analyses if applicable Discussion including findings into context, implications of findings, applicability of findings, limitations, gaps, etc Conclusions and recommendations Appendices Sample search strategy Bibliography of included and excluded studies (with reasons for exclusion) Evidence tables Example completed quality appraisal checklist. The PHAC may request further clarification or work during their discussions at the committee meeting. Following the PHAC meeting the contractors will discuss and agree with the NICE team any required further work or amendments to the review. Amendments to the evidence review should be made within 10 working days of the committee meeting.

Presentation of products. The contractor will produce a written manuscript in MS Word for the draft and final evidence review. The final style and format of the products will be agreed by NICE Team and the PDG. The production will be undertaken according to the methodology set out in the Methods for development of NICE public health guidance 2012 and as summarised below. Example manuscripts will be provided by NICE Team. The draft and final reviews will address the research questions, the populations groups, areas and outcomes identified in the final Scope (sections 4.1, 4.2, 4.4 and 4.5) and used in the original evidence reviews. The detailed parameters, style and format of the draft and final reports are to be agreed with the NICE Team before writing commences. A stand-alone executive summary is to be included in the draft and final reviews. The executive summary will include all of the evidence statements (see Chapter 5 and 6 of the Methods for development of NICE public health guidance 2012) and the linked references. At least one draft manuscript is to be submitted first, this is commented on by the NICE Team and then the final draft manuscript is prepared in line with comments received and re-submitted to NICE team in readiness for mailing to the PHAC. The NICE team will ensure that the finalised draft will then be forwarded to the PHAC. See Annex 2 for the required timetable for the production of the draft and final reviews. The reviews will remain strictly confidential until the guidance consultation phase. Draft and final reviews will review should include the following areas (further details are provided in Appendix L of the methods manual): following: Executive summary Introduction Context in which the review is set Aims and objectives of the review Research questions Operational definitions Identification of possible equality and equity issues Review team Methodology Literature search and abstract appraisal Retrieval of data and full paper appraisal (including inclusion/exclusion criteria) Selection of studies for inclusion (including flow diagram which is to be adapted from NICE template) Quality assessment and applicability appraising Methods of data extraction, synthesis and presentation (including formulation of evidence statements) Findings Overview of studies for each research question Narrative summary of the evidence for each selected theme Evidence statements for each selected theme Applicability of the evidence to the UK populations in the scope Meta-analyses if applicable Discussion including findings into context, implications of findings, applicability of findings, limitations, gaps, etc gaps in the evidence Conclusions and recommendations Appendices Sample Search protocol & base search strategy (typically the full Medline strategy) Bibliography of included and excluded studies (with reasons for exclusion) Evidence tables – evidence tables are to report effect size and 95% CI when this information is reported in the studies. Where the information is not available this needs clearly stating in the evidence table and whatever analysis is reported in the study can be used instead Example completed quality appraisal checklistappraisal. The PHAC detailed style and format of the draft and final style evidence review will be agreed by NICE Team. Example evidence reviews can be provided by NICE Team if required. A draft manuscript is to be submitted first, this is commented on by the NICE Team and then the final draft manuscript is prepared in line with comments received and re-submitted to NICE team in readiness for mailing to SSAC. The NICE team will ensure that the finalised draft will then be forwarded to SSAC. See Annex 2 for the required timetable for the production of the draft and final evidence. The evidence review will remain strictly confidential until the guidance consultation phase. The SSAC may request further clarification or work during their discussions at the committee meeting. Following the PHAC SSAC meeting the contractors will discuss and agree with the NICE team any required further work or amendments to the evidence review. Amendments to the evidence review should be made within 10 working days of prior to the committee meetingdraft guideline consultation stage.

Presentation of products. The contractor will produce a written manuscript in MS Word for the draft and final review. The final style and format of the products will be agreed by NICE Team and the PDG. The production will be undertaken according to the methodology set out in the Methods for development of NICE public health guidance 2012 2009 and as summarised below. Example manuscripts will be provided by NICE Team. The draft and final reviews will address the research questions, the populations groups, areas and outcomes identified in the final Scope (sections 4.1, 4.2, 4.4 and 4.5) and used in the original evidence reviews). The detailed parameters, style and format of the draft and final reports are to be agreed with the NICE Team before writing commences. A stand-alone executive summary is to be included in the draft and final reviews. The executive summary will include all of the evidence statements (see Chapter 5 and 6 of the Methods for development of NICE public health guidance 20122009) and the linked references. At least one draft manuscript is to be submitted first, this is commented on by the NICE Team and then the final draft manuscript is prepared in line with comments received and re-re- submitted to NICE team in readiness for mailing to the PHACPDG. The NICE team will ensure that the finalised draft will then be forwarded to the PHACPDG. See Annex 2 for the required timetable for the production of the draft and final reviews. The reviews will remain strictly confidential until the guidance consultation phase. Draft and final reviews will include the following areas (further details are provided in Appendix L of the methods manual): Executive summary Introduction o Context in which the review is set o Aims and objectives of the review o Research questions o Operational definitions o Identification of possible equality and equity issues o Review team Methodology o Literature search and abstract appraisal o Retrieval of data and full paper appraisal (including inclusion/exclusion criteria) o Selection of studies for inclusion (including flow diagram which is to be adapted from NICE template) o Quality assessment and applicability appraising o Methods of data extraction, synthesis and presentation (including formulation of evidence statements) Findings o Overview of studies for each research question o Narrative summary of the evidence for each selected theme o Evidence statements for each selected theme o Applicability of the evidence to the UK populations in the scope o Meta-analyses if applicable Discussion including findings into context, implications of findings, applicability of findings, limitations, gaps, etc Conclusions and recommendations Appendices o Sample search strategy o Bibliography of included and excluded studies (with reasons for exclusion) o Evidence tables o Example completed quality appraisal checklist. The PHAC PDG may request further clarification or work during their discussions at the committee meeting. Following the PHAC PDG meeting the contractors will discuss and agree with the NICE team any required further work or amendments to the review. Amendments to the evidence review should be made within 10 working days of the committee meeting.

Presentation of products. The contractor will produce a written manuscript in MS Word for the draft and final review. The final style and format of the products will be agreed by NICE Team and the PDG. The production will be undertaken according to the methodology set out in the Methods for development of NICE public health guidance 2012 and as summarised below. Example manuscripts will be provided by NICE Team. The draft and final reviews will address the research questions, the populations groups, areas and outcomes identified in the final Scope (sections 4.1, 4.2, 4.4 and 4.5) and used in the original evidence reviews. review protocol The detailed parameters, style and format of the draft and final reports are to be agreed with the NICE Team before writing commences. A stand-alone executive summary is to be included in the draft and final reviews. The executive summary will include all of the evidence statements (see Chapter 5 and 6 of the Methods for development of NICE public health guidance 2012) and the linked references. At least one draft manuscript is to be submitted first, this is commented on by the NICE Team and then the final draft manuscript is prepared in line with comments received and re-submitted to NICE team in readiness for mailing to the PHAC. The NICE team will ensure that the finalised draft will then be forwarded to the PHAC. See Annex 2 for the required timetable for the production of the draft and final reviews. The reviews will remain strictly confidential until the guidance consultation phase. Draft and final reviews reports will include the following areas (further details are provided in Appendix L of the methods manual): Executive summary Introduction Context in which the review is set Aims and objectives of the review Research questions Operational definitions Identification of possible equality and equity issues Review team Methodology Literature search and abstract appraisal Retrieval of data and full paper appraisal (including inclusion/exclusion criteria) Selection of studies for inclusion (including flow diagram which is to be adapted from NICE template) Quality assessment and applicability appraising Methods of data extraction, synthesis and presentation (including formulation of evidence statements) Findings Overview of studies for each research question Narrative summary of the evidence for each selected theme Evidence statements for each selected theme Applicability of the evidence to the UK populations in the scope Meta-analyses if applicable Discussion including findings into context, implications of findings, applicability of findings, limitations, gaps, etc Conclusions and recommendations Appendices Sample search strategy Bibliography of included and excluded studies (with reasons for exclusion) Evidence tables Example completed quality appraisal checklist. The PHAC may request further clarification or work during their discussions at the committee meeting. Following the PHAC meeting the contractors will discuss and agree with the NICE team any required further work or amendments to the review. Amendments to the evidence review should be made within 10 working days of the committee meeting.